Close menu




January 14th, 2020 | 10:54 CET

Ballard Power, dynaCERT, Tesla - the strength of innovations and solutions

  • Innovations
Photo credits: pixabay.com

On the capital market investors find an infinite variety of possibilities to invest their money. There are listed companies that have a history and are valued on the basis of compliance with prospects and fundamentals. And then there are innovative companies that attract capital regardless of all valuation parameters because they have a product that solves problems and arouses desires. If the product is also scalable, then the potential of the shares is often exorbitant, depending on the market size.

time to read: 1 minutes | Author: Mario Hose
ISIN: CA26780A1084 , CA0585861085 , US88160R1014

Table of contents:


    Ballard Power with hydrogen

    The Canadian fuel cell manufacturer Ballard Power has experienced a veritable price rally over the past 12 months. During this period, the company's share price rose from below EUR 2.80 to over EUR 9.50. The shareholders were able to achieve a return of over 230%.

    The market capitalization is now quoted at over 2 billion EUR. The topic of hydrogen in modern mobility is gaining more and more interest and based on that investors are looking for investment opportunities that are active in this field with scalable products.

    dynaCERT makes diesel greener

    Also located in Canada is the innovative company dynaCERT. After more than 15 years of research and development, the experts for hydrogen technologies were able to bring a device to series production readiness with which diesel engines can be retrofitted. The advantage of the technology is that the consumption of diesel can be reduced by up to 18% and, in addition, emissions of NOx, carbon dioxide and particulate matter are also significantly reduced.

    As currently circa one billion diesel engines are in operation and the use of dynaCERT's HydraGEN technology not only offers high savings in fuel consumption but also protects the environment, the share price could increase from below EUR 0.17 to over EUR 0.72 in the past 12 months. With a market value of EUR 230 million, the company is still a lightweight compared to Ballard Power.

    Tesla and the battery car

    Tesla from the USA is a prime example of a new trend. The manufacturer of battery cars has been the focus of reporting for over a decade. The founder at the top of the company is Elon Musk. He is driving Tesla's innovations forward and his announcements are causing euphoria and imagination on the capital market. It's hard to imagine that Tesla today would have a valuation of over EUR 81 billion if Tesla had been led by an employed CEO over the past ten years.

    Musk is there with passion and emotion, and this is the only way to keep the company continuously alive with new cash injections. The share price increased by over 60% from EUR 290.00 to EUR 475.00 in the comparison period. Ten years ago, Tesla shares changed hands at less than EUR 15.00, which clearly shows how enormous the potential of innovations and trends can be.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Mario Hose

    Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

    About the author



    Related comments:

    Commented by André Will-Laudien on June 24th, 2026 | 08:45 CEST

    AI and Chip Sell-Off! Watch Out for SMCI, AMD, and Infineon; First Hydrogen in the Innovation Race

    • Hydrogen
    • cleantech
    • chips
    • AI
    • Innovations
    • Software
    • semiconductor

    The stock market is currently showing no mercy. After months of gains in AI, high-tech, and chip stocks, the market has now shifted into profit-taking mode—and, at times, even sell-off mode. What analysts have been predicting for quite some time is increasingly coming to pass. The global stock market rally, driven by the NASDAQ, is taking its toll. While the long-term earnings outlook may be solid, short-term price surges of up to 2,000% in just 12 months no longer indicate a healthy market trend. So, while it comes as no surprise, it may be unwelcome for many market participants: a sharper downward move—one that, however, also brings new opportunities in its wake. We examine the fundamental framework of the key players and highlight alternatives for getting off to an innovative start today. The stock market keeps turning—just a little slower at times!

    Read

    Commented by Tarik Dede on June 24th, 2026 | 08:05 CEST

    Innovation in Research: Opportunities at Vertex Pharmaceuticals, BioNxt Solutions, and BioNTech

    • Biotechnology
    • Biotech
    • Pharma
    • Innovations

    On social media, you can find all sorts of negative comments and memes about the Pfizer Corporation. One very popular one claims that the company—founded in New York by German immigrants (Karl Pfizer and Karl Erhart)—has never cured a single disease in its 177-year history. This is at least partly true, as Pfizer—particularly for chronic, widespread conditions like high blood pressure or high cholesterol—focuses on treating symptoms rather than the underlying causes. However, it is also true that during World War II, Pfizer was the world's first and largest mass producer of penicillin. Critics level this same accusation against many pharmaceutical companies. Nevertheless, there are numerous companies working on innovative approaches to truly defeat diseases and improve people's lives. And, of course, they also aim to make a lot of money in the process. That is why we are taking a look today at the stocks of Vertex Pharmaceuticals, BioNxt Solutions, and BioNTech.

    Read

    Commented by Nico Popp on June 18th, 2026 | 07:35 CEST

    The Secret Mechanism That Kills Cancer Cells: What Revolution Medicines and Merck & Co. Need to Learn from Vidac Pharma

    • Biotechnology
    • Biotech
    • Pharma
    • Cancer
    • Innovations

    There is, without exaggeration, a looming "patent cliff" of enormous scale: an estimated USD 236 billion in annual revenue losses are forcing the biopharmaceutical industry to find new paths forward. Pharma giants must replace dwindling blockbuster revenues by strategically acquiring innovative oncology platforms, as conventional cancer therapies are increasingly reaching their limits. This innovation pressure is triggering a consolidation wave in which research-driven biotech companies with protected mechanisms of action are moving into the center of potential takeover activity. In particular, intracellular and metabolic treatment approaches are rapidly gaining importance in the fight against treatment-resistant cancers. We take a look at Revolution Medicines' successes and identify the next potential high-flyer.

    Read